Use of antibiotic in contraceptive trial sparks controversyBMJ 2004; 328 doi: http://dx.doi.org/10.1136/bmj.328.7433.188-a (Published 22 January 2004) Cite this as: BMJ 2004;328:188
- Ganapati Mudur
- New Delhi
A clinical trial in India's West Bengal state evaluating the antibiotic erythromycin as a female contraceptive has sparked controversy 15 months after the study ended, with doctors accused of pursuing illegal and unethical research.
A paper published this month in the international journal Contraception (2004;69:47-9) says that transcervical administration of erythromycin seemed very safe but had an “unacceptably high” failure rate of 28-35% per cent after 12 months. The volunteers were divide into two groups. Each woman in the first group received a 500mg tablet of erythromycin, while each woman in the second group received ten 50mg pellets of the drug. In both cases thetablets or pellets were placed in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial